KEAP1 and acute respiratory distress syndrome: Significant modifications in NFE2L2-KEAP1 pathways have been observed in patients with severe infectious progression, various conditions of acute lung injury (ALI), acute respiratory distress syndrome (ARDS), respiratory failure, heart failure, sepsis, and sudden cardiac arrest [15,16].